- Home
- PBT vs KALV Comparison
PBT vs KALV Comparison
Compare PBT & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBT
- KALV
- Stock Information
- Founded
- PBT 1980
- KALV N/A
- Country
- PBT United States
- KALV United States
- Employees
- PBT N/A
- KALV N/A
- Industry
- PBT Oil & Gas Production
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- PBT Energy
- KALV Health Care
- Exchange
- PBT Nasdaq
- KALV Nasdaq
- Market Cap
- PBT 475.4M
- KALV 563.1M
- IPO Year
- PBT N/A
- KALV N/A
- Fundamental
- Price
- PBT $10.29
- KALV $11.04
- Analyst Decision
- PBT
- KALV Strong Buy
- Analyst Count
- PBT 0
- KALV 8
- Target Price
- PBT N/A
- KALV $24.83
- AVG Volume (30 Days)
- PBT 99.0K
- KALV 552.8K
- Earning Date
- PBT 01-01-0001
- KALV 03-12-2025
- Dividend Yield
- PBT 4.70%
- KALV N/A
- EPS Growth
- PBT N/A
- KALV N/A
- EPS
- PBT 0.55
- KALV N/A
- Revenue
- PBT $27,114,144.00
- KALV N/A
- Revenue This Year
- PBT N/A
- KALV N/A
- Revenue Next Year
- PBT N/A
- KALV N/A
- P/E Ratio
- PBT $18.52
- KALV N/A
- Revenue Growth
- PBT N/A
- KALV N/A
- 52 Week Low
- PBT $9.43
- KALV $7.30
- 52 Week High
- PBT $14.26
- KALV $15.50
- Technical
- Relative Strength Index (RSI)
- PBT 50.75
- KALV 42.52
- Support Level
- PBT $9.72
- KALV $11.83
- Resistance Level
- PBT $10.51
- KALV $11.78
- Average True Range (ATR)
- PBT 0.34
- KALV 0.57
- MACD
- PBT 0.05
- KALV -0.23
- Stochastic Oscillator
- PBT 72.15
- KALV 8.42
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.